| Protocol |
Title |
Status |
Contact |
| 103760 |
A Randomized Phase III Trial of Preoperative Compared to Post Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases |
OPEN TO ACCRUAL |
 |
| 103514 |
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE 102) |
OPEN TO ACCRUAL |
|
| 103749 |
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
OPEN TO ACCRUAL |
|
| 103518 |
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF ß Antagonist/IL 15 Protein Complex, for Advanced Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103392 |
A Phase 1/2 Study of NM21 1480 (Anti PDL 1/Anti 4 1BB/Anti HSA Tri Specific Antibody) in Adult Patients With Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103699 |
PHASE III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First Line Platinum Based Chemotherapy in Patients With Metastatic Urothelial Cancer |
OPEN TO ACCRUAL |
|
| 103491 |
A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy |
OPEN TO ACCRUAL |
|
| 103714 |
A Phase II Randomized Trial of Olaparib (NSC 747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. |
OPEN TO ACCRUAL |
|
| 103472 |
T Reg Function Changes: A Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer |
OPEN TO ACCRUAL |
|
| 103715 |
A Randomized Phase II Study Comparing Single Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi Arm Trial for Women with Recurrent or Persistent Endometrial Cancer |
OPEN TO ACCRUAL |
|
| 103681 |
Phase III Trial of Immunotherapy Based Combination Therapy With or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (PROBE TRIAL) |
OPEN TO ACCRUAL |
|
| 103668 |
Phase III Trial of Salvage Stereotatic Radiosurgery (SRS) or SRS + Hippocampalacodiant Whole Brain Radiotherapy (HA WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brian Metastasis Velocity =4 Brian Metastases/ Year |
OPEN TO ACCRUAL |
|
| 103488 |
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B Acute Lymphoblastic Leukemia (B ALL) |
OPEN TO ACCRUAL |
|
| 103722 |
Melanoma Margins Trial (MelMarT II): A Phase III, Multi Centre, Multi National Randomized Control Trial investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma |
OPEN TO ACCRUAL |
|
| 103560 |
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|
| 103627 |
Randomized Phase II/III Trial of Radiation with High Dose Cisplatin (100mg/m2) Every Three Weeks Versus Radiation with Low Dose Cisplatin (40mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
OPEN TO ACCRUAL |
|
| 103632 |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD L1 Negative, Advanced Non Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103664 |
Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post Prostatectomy Biochemical Recurrence (INDICATE) |
OPEN TO ACCRUAL |
|
| 103643 |
A Phase II/III Study of N 803 (ALT 803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non Small Cell Lung Cancer Previously Treated With Anti PD 1 or Anti PD L1 Therapy (Lung MAP Non Match Sub Study) |
OPEN TO ACCRUAL |
|
| 103506 |
A Phase 3 Randomized Non Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) |
OPEN TO ACCRUAL |
|